OCM
NKTR icon

Osterweis Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Osterweis Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,474
Closed -$6.59M – 154
2021
Q3 		$6.59M Sell
24,474
-417
-2% -$100K 0.36% 79
2021
Q2 		$6.41M Sell
24,891
-1,438
-5% -$398K 0.33% 84
2021
Q1 		$7.9M Sell
26,329
-1,971
-7% -$613K 0.43% 68
2020
Q4 		$7.22M Sell
28,300
-3,500
-11% -$904K 0.43% 68
2020
Q3 		$7.91M Sell
31,800
-1,106
-3% -$348K 0.53% 54
2020
Q2 		$11.4M Sell
32,906
-12,194
-27% -$3.81M 0.83% 44
2020
Q1 		$12.1M Buy
45,100
+27,291
+153% +$8.44M 0.98% 41
2019
Q4 		$5.77M Sell
17,809
-7,148
-29% -$2.07M 0.4% 57
2019
Q3 		$6.82M Buy
24,957
+10,271
+70% +$3.77M 0.5% 48
2019
Q2 		$7.84M Buy
+14,686
New +$7.36M 0.55% 48

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Osterweis Capital Management's NKTR Position: Q4 2021 in Review

Osterweis Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 24,474 shares — an estimated $6.59M sold.

Osterweis Capital Management first reported a position in NKTR in Q2 2019 and held it in 10 quarters. The position peaked at $12.1M in Q1 2020. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Osterweis Capital Management reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Osterweis Capital Management sold 24,474 Nektar Therapeutics shares in Q4 2021, an estimated $6.59M.
  • Osterweis Capital Management first reported a position in Nektar Therapeutics in Q2 2019 and held it in 10 quarters.
  • Osterweis Capital Management's Nektar Therapeutics position peaked at $12.1M in Q1 2020.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Osterweis Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.